Intravenous immunoglobulin (IVIG) therapy is a well-documented and effective treatment for primary immunodeficiencies (PI). Subcutaneous immunoglobulins (SCIG) have emerged as an effective alternative for some patients that offers additional flexibility.Currently, caprylate/chromatography purified IGSC (human) 20% is approved to treat PI in North America and many countries worldwide. In this multi-center, open-label study, the pharmacokinetics (PK), efficacy, and safety of IGSC 20% were studied after biweekly (every two weeks) dosing for 16 weeks and compared to weekly IGSC 20% administration for 16 weeks in treatment-experienced PI patients. A loading/weekly maintenance SC regimen was also studied in PI patients naïve to IG treatment.In treatment-experienced patients, the least squares mean ratio of steady-state AUC0−7 days for biweekly dosing showed non-inferiority to weekly dosing (90% confidence interval 1.0030–1.0685). Other PK parameters (Cmax, Tmax, steady state trough) were similar between treatments. Efficacy and safety measures were qualitatively similar to previously published results. No serious bacterial infections were reported. Annual rates for any type of infection were similar between the treatment groups. All severe treatment-related adverse events (AEs) were unrelated to treatment. Only mild to moderate suspected adverse drug reactions were observed.PK analyses showed that biweekly dosing of IGSC 20% was non-inferior to weekly dosing in treatment-experienced PI patients. Biweekly dosing had similar patterns to weekly in prevention of serious bacterial infections, rates of all infections and hospitalizations for infections. The IGSC loading/maintenance dosing regimen in naïve patients was safe and effective during the observation period.
PK analyses showed that biweekly dosing of IGSC 20% was non-inferior to weekly dosing in treatment-experienced PI patients.
prespecified within-subject AUC comparison met the regulatory non-inferiority threshold with a lower 90% confidence bound above 0.80
IGSC 20% showed qualitatively similar efficacy to previous studies.
infection outcomes were descriptive in a small study not designed or powered for efficacy
The IGSC loading/maintenance dosing regimen in naïve patients was safe and effective during the observation period.
the claim rests on six participants, dose adjustment in half, and descriptive safety and infection observations
Derived from the full evaluation — not a separate score.
Strengths
The AUC comparison uses a prespecified lower 90% confidence-bound criterion of 0.80, and the observed ratio of 1.035 with a 90% CI of 1.0030–1.0685 meets that criterion.
↳ Methods, Objectives; Results, Pharmacokinetic Endpoints; Table 2
The Introduction states that biweekly administration was added to the US product label on the basis of this study, establishing a direct route from evidence to prescribing information.
↳ Introduction, paragraph 5
The Caveats paragraph states that the study was not designed or powered for efficacy and that those measures should not be considered conclusive. The conclusion accordingly describes efficacy only as qualitatively similar to previous studies.
↳ Discussion, Caveats and Overall paragraphs
Limitations
All treatment-experienced participants received weekly dosing before biweekly dosing, so regimen frequency is inseparable from treatment period. The Discussion does not address this design limitation.
↳ Methods, Study Design; Figure 1; Discussion, Caveats
The study treated 27 experienced and six naïve patients; all were Caucasian and nearly all had CVID. The naïve regimen and broader PI-population conclusions therefore rest on narrow evidence.
↳ Results, Patient Characteristics and Disposition; Table 1
The Abstract inconsistently calls severe events treatment-related and unrelated, while the Methods reports consent but no ethics-committee or IRB approval declaration. Detailed safety results clarify the event classification but not the oversight omission.
↳ Abstract; Methods, Inclusion and Exclusion Criteria; Results, Safety Endpoints; Table 5
The primary PK result is supported by a prespecified within-subject AUC comparison whose confidence interval comfortably exceeds the non-inferiority threshold in Table 2. The contribution is nevertheless confirmatory, extending prior modelling and analogous-product evidence to this specific product rather than introducing a new dosing concept. Methodological credit is tempered by the fixed weekly-to-biweekly sequence and limited examination of exclusions from the primary PK population. The paper appropriately limits efficacy interpretation in the Discussion, while the enacted US label expansion gives the findings a concrete translational role.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Sound3.4
Confidence highThe study adds direct product-specific clinical confirmation that biweekly IGSC 20% preserves systemic IgG exposure and reports that this evidence supported a US label expansion. The advance remains incremental because it verifies prior modelling and parallels clinical evidence for another SCIG product.
“biweekly administration was added to the US product label on the basis of the study reported herein”
The prespecified AUC endpoint, within-subject mixed-effects model, and regulatory non-inferiority criterion directly address the primary PK question. Fixed weekly-to-biweekly order and the reduction from 27 enrolled to 23 primary-PK participants introduce uncertainty that is not fully examined.
“with treatment period (weekly or biweekly) as a fixed effect and subject as a random effect”
The paper states the non-inferiority criterion and numerical result precisely and repeatedly distinguishes the primary PK conclusion from descriptive efficacy findings. One Abstract sentence incorrectly labels severe events as treatment-related before calling them unrelated, but the detailed safety section resolves the intended meaning.
“efficacy measures are only qualitative and descriptive and should not be considered conclusive”
The Discussion connects the findings to the pivotal IGSC 20% study, prior PK modelling, and analogous Hizentra evidence. It also carries the small naïve cohort, short PK-focused duration, and lack of efficacy power into appropriately restricted interpretation, although the fixed-sequence limitation is not discussed.
“This study was not designed or powered as an efficacy trial.”
Lower confidence on Contribution, Methodological Rigour — domain match limited.
Caveats4 of 4 checks
The primary PK estimates are consistent across the Abstract, Results, and Table 2, but one Abstract safety sentence uses internally contradictory causality terminology. The detailed safety reporting indicates that severe TEAEs were unrelated and that suspected ADRs were mild or moderate.
Written informed consent is specified, but the supplied multicentre clinical-study report does not declare ethics-committee or IRB approval. No conflict-of-interest disclosure is present in the supplied article.
Flags: 0 declared / 5 total
61 of 61 checkable references verified
64 references in manuscript 3 are books, websites or datasets — counted, but not index-checkable
References not verified automatically are resolved manually within 24 hours.
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Correction published 02 Feb 2026 · listed in Crossref
Sources: Crossref (incl. Retraction Watch) ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
Readiness is advanced because the clinical PK evidence has already supported addition of biweekly dosing to the US product label. Descriptive efficacy evidence limits what can be inferred beyond exposure equivalence but does not undo the completed regulatory use.
“biweekly administration was added to the US product label”
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
Goudouris, Pinto-Mariz, Mendonça, et al. · 2021 · Clinical medicine
The outcome was mild in most patients, but the Case Fatality Ratio was higher than in the general population.
TentativePerez, Hébert, Ellis, et al. · 2021 · Basic medicine
A single acute serious bacterial infection occurred during the study, resulting in an incidence of 0.02 events per patient-year (upper 99% one-sided confidence interval limit: 0.21), meeting the prespecified primary efficacy endpoint.
Well-supportedThe long ZAP isoform preferentially binds viral RNA and has distinct binding motifs compared to the short isoform.
Supported